Precigen, Inc. (PGEN)
Automate Your Wheel Strategy on PGEN
With Tiblio's Option Bot, you can configure your own wheel strategy including PGEN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PGEN
- Rev/Share 0.0143
- Book/Share -0.0478
- PB -31.1438
- Debt/Equity -0.3853
- CurrentRatio 3.5271
- ROIC -1.2459
- MktCap 439818200.0
- FreeCF/Share -0.2561
- PFCF -5.8438
- PE -2.7953
- Debt/Assets 0.0421
- DivYield 0
- ROE -5.0944
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript
Published: March 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Precigen, Inc. (NASDAQ:PGEN ) Q4 2024 Earnings Conference Call March 19, 2025 4:30 PM ET Company Participants Steven Harasym - IR Helen Sabzevari - President and CEO Rutul Shah - COO Phil Tennant - CCO Harry Thomasian - CFO Conference Call Participants Jason Butler - Citizens Carolina Ibanez Ventoso - Stifel Swayampakula Ramakanth - H.C. Wainwright Jennifer Kim - Cantor Brian Cheng - JPMorgan Operator Good evening, and welcome to the Precigen's Full Year 2024 Financial Results and Business Update Call.
Read More
Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates
Published: March 19, 2025 by: Zacks Investment Research
Sentiment: Negative
Precigen, Inc. (PGEN) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.09 per share a year ago.
Read More
Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Positive
BLA of PRGN-2012 for patients with Recurrent Respiratory Papillomatosis was accepted by FDA with a Priority Review date of August 27th of 2025. Marketing approval of PRGN-2012 for RRP would be huge because there is no FDA approved drugs for RRP. Also, there are an estimated 27,000 people in the United States who have it. PGEN is looking to form a strategic partnership or collaboration agreement to advance its UltraCAR-Ts. This technology is crucial because it could change CAR-T landscape for the better.
Read More
Precigen, Inc. (PGEN) Just Flashed Golden Cross Signal: Do You Buy?
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Precigen, Inc. (PGEN) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, PGEN's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Read More
About Precigen, Inc. (PGEN)
- IPO Date 2013-08-08
- Website https://www.precigen.com
- Industry Biotechnology
- CEO Dr. Helen Sabzevari MPH, Ph.D.
- Employees 143